AVIR Atea Pharmaceuticals, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1593899 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-5.7%
TTM EPS YoY-10.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-63.2%
ROA-57.2%
ROIC (approx.)-86.0%
Asset turnover—
Leverage & solvency
Liabilities / assets12.5%
Debt / equity0.00x
Current ratio8.00x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.90x
Accruals ratio-5.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | $351.37M |
| R&D expense | $148.02M | $144.10M | $114.24M | $81.94M | $167.21M |
| SG&A expense | $32.86M | $48.85M | $49.92M | $48.71M | $45.78M |
| Operating income | -$180.89M | -$192.95M | -$164.16M | -$130.65M | $138.38M |
| Pretax income | -$164.51M | -$167.46M | -$134.94M | -$119.50M | $138.59M |
| Income tax | -$6.16M | $925,000 | $1.02M | -$3.59M | $17.40M |
| Net income | -$158.35M | -$168.38M | -$135.96M | -$115.91M | $121.19M |
| EBITDA | -$180.47M | -$192.53M | -$163.75M | -$130.39M | $138.41M |
| EPS (basic) | -1.94 | -2.00 | -1.63 | -1.39 | 1.46 |
| EPS (diluted) | -1.94 | -2.00 | -1.63 | -1.39 | 1.37 |
| Weighted avg. shares (diluted) | 81.50M | 84.26M | 83.39M | 83.25M | 88.25M |
| Balance sheet | |||||
| Cash & equivalents | $95.71M | $64.70M | $143.82M | $188.66M | $764.68M |
| Short-term investments | $206.12M | $390.02M | $434.28M | $458.25M | — |
| Current assets | $310.99M | $462.36M | $590.46M | $660.92M | $772.40M |
| PP&E, net | $457,000 | $873,000 | $1.29M | $1.71M | $23,000 |
| Total assets | $315.22M | $464.67M | $594.97M | $666.71M | $772.89M |
| Current liabilities | $39.78M | $18.60M | $32.38M | $18.48M | $56.88M |
| Total liabilities | $39.78M | $25.80M | $39.78M | $26.14M | $62.81M |
| Shareholders' equity | $275.43M | $438.87M | $555.19M | $640.57M | $710.08M |
| Shares outstanding | 78.13M | 84.46M | 83.44M | 83.29M | 83.10M |
| Cash flow statement | |||||
| Operating cash flow | -$132.03M | -$135.50M | -$85.39M | -$120.98M | -$87.00M |
| Capital expenditure | — | — | — | $1.94M | $4,000 |
| Free cash flow | — | — | — | -$122.92M | -$87.01M |
| Investing cash flow | $188.79M | $56.10M | $40.30M | -$455.41M | -$4,000 |
| Financing cash flow | -$25.75M | $267,000 | $257,000 | $370,000 | $1.47M |
| Depreciation & amortization | $416,000 | $416,000 | $416,000 | $260,000 | $29,000 |
| Stock-based compensation | $20.72M | $51.77M | $49.43M | $46.72M | $39.62M |
| Share buybacks | $25.52M | $0 | — | — | — |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.